LAVA Therapeutics Q4 2024 Earnings Report

LAVA Therapeutics EPS Results

• Actual EPS: -$0.14
• Consensus EPS: -$0.32
• Beat/Miss: Beat by +$0.18
• One Year Ago EPS: N/A

LAVA Therapeutics Revenue Results

• Actual Revenue: $2.50 million
• Expected Revenue: $2.40 million
• Beat/Miss: Beat by +$104.00 thousand
• YoY Revenue Growth: N/A

LAVA Therapeutics Announcement Details

• Quarter: Q4 2024
• Date: 3/28/2025
• Time: Before Market Opens

LAVA Therapeutics (NASDAQ:LVTX) N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.